PODCAST
Your Thyroid, Your Hot Flashes, and One HRT Drug Worth Knowing About
September 2, 2026·8:54·Episode 115
Quick Summary
Three new findings worth knowing about: research suggesting thyroid changes in midlife are more about aging than menopause, a nationwide cohort study linking the hormone therapy tibolone to elevated liver cancer risk, and new evidence that frequent hot flashes may signal reduced blood vessel function — not just discomfort.
Your Thyroid, Your Hot Flashes, and One HRT Drug Worth Knowing About
0:000:00
Key Takeaways
- ✦Thyroid function does shift in midlife, but new research points to aging as the main driver — not menopause itself — meaning the two conditions need to be evaluated separately, not assumed to be the same problem.
- ✦Tibolone, a synthetic hormone therapy widely used outside the US, was associated with a meaningfully higher risk of liver cancer in a large nationwide cohort study published September 1, 2026 — women using it should discuss this finding with their doctor.
- ✦Frequent hot flashes are linked to measurably reduced function in the small blood vessels — a sign the cardiovascular system may be under stress, not just a nuisance symptom to wait out.
- ✦Not all hormone therapies carry the same risks; tibolone works differently in the body than standard estrogen-based HRT, and its risk profile appears to differ as well.
- ✦Hot flash frequency matters clinically — the more frequent they are, the more reason to treat them, and potentially the more reason to view them as a signal worth taking seriously with your doctor.
Sources & References
Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.